Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management [PDF]
, 2017 BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal-dominant hereditary disorder of lipid metabolism that causes lifelong exposure to increased LDL levels resulting in premature coronary heart disease and, if untreated, death.
Baccolini, Valentina +6 more
core +2 more sources
The FEBS Journal, EarlyView.High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz +9 more
wiley +1 more source
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk:Rationale and design of the ODYSSEY DM-INSULIN trial [PDF]
, 2017 Aims: The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study.
A. Letierce +49 more
core +1 more source
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Lipids in Health and Disease, 2008 Background Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density lipoprotein cholesterol (LDLC) by negatively regulating ...
Mbikay Majambu +9 more
doaj +1 more source
Thrombosis Journal, 2021 Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is considered to have multiple roles in the development of atherosclerosis, which is recently reported to participate in the thrombotic process. We aimed to examine the relationship between
Jia Peng +9 more
doaj +1 more source
Experimental Physiology, EarlyView.Abstract Current literature on the metabolic effects of long‐distance hiking is limited to case studies with discrepant findings, and no prior studies have examined the role of diet in shaping these outcomes. In this study, we investigated changes in lipid profiles and dietary factors among 12 participants who completed the Colorado Trail.
Kiaya Johnston +3 more
wiley +1 more source
Outcome-based pricing for new pharmaceuticals via rebates [PDF]
, 2020 The price of new brand-name prescription drugs has been rising fast in the United States. For example, the Amgen cholesterol drug Repatha had an initial list price of $14,523 per year.
Adida, E
core
Rethinking Statin Dosage in Coronary Disease
Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.It is widely acknowledged that a sufficient statin dose is important in the management of symptomatic coronary disease, along with weight reduction and appropriate antithrombotic, blood pressure, and diabetes pharmacotherapy. Mid‐range statin doses have been shown to achieve the maximum improvements in total mortality and have the advantage of greater ...
Simon B. Dimmitt +3 more
wiley +1 more source
The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis [PDF]
, 2015 BACKGROUND: Studies had investigated the associations between proprotein convertase subtilisin/kexin type 9 (PCSK9) E670G polymorphism and coronary artery disease (CAD) and lipid levels, but the results were controversial.
Bifeng Zhang +6 more
core +2 more sources
PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology [PDF]
, 2022 Tereza Altschmiedová +4 more
openalex +1 more source